Related Experiment Video
Updated: Mar 11, 2026
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial learning and memory ability
Xiaohui Wang1, Li Wang1, Ruirui Jiang1
1Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Abstract:
β-amyloid protein (Aβ) accumulation in cerebral centers involved in cognition and memory is a pivotal pathological feature of Alzheimer's disease (AD). The onset process of type 2 diabetes mellitus (T2DM) has a number of similarities compared with AD. Thus, it is hypothesized that the pharmacological therapy employed for the treatment of T2DM may help to prevent and ameliorate the symptoms of AD. This study demonstrated that Exendin-4, which is a glucagon-like peptide-1 analogue which is used as a therapeutic drug for T2DM, markedly antagonized Aβ fragment-induced attenuation of spatial learning and memory ability, as indicated by a Morris water maze experiment. In addition, we investigated the potential underlying electrophysiological and molecular mechanisms. The results indicate that Exendin-4 rescued long-term potentiation from Aβ1-42-induced damage in the rat hippocampal CA1 region in vivo, and antagonized Aβ1-42-induced reduction of cyclic adenosine monophosphate and phosphorylated-cAMP response element-binding protein in rat hippocampal tissue using ELISA and western blot analysis, respectively. Thus, the results of the present study provide theoretical support for the application of Exendin-4 for improving AD.
Insights
Exendin-4, a type 2 diabetes treatment, improved spatial learning and memory in rats by counteracting beta-amyloid effects. This suggests potential for Exendin-4 in Alzheimer's disease therapy.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) protein accumulation impacting cognition.
- Type 2 diabetes mellitus (T2DM) shares pathological similarities with AD onset.
- T2DM pharmacotherapies may offer therapeutic benefits for AD.
Purpose of the Study:
- To investigate if Exendin-4, a T2DM drug, can prevent and ameliorate AD symptoms.
- To explore the electrophysiological and molecular mechanisms of Exendin-4's effects on Aβ-induced cognitive impairment.
Main Methods:
- Morris water maze experiment to assess spatial learning and memory.
- In vivo electrophysiological recordings in rat hippocampal CA1 region.
- ELISA and western blot analysis to measure cyclic adenosine monophosphate (cAMP) and phosphorylated-cAMP response element-binding protein (pCREB) levels.
Main Results:
- Exendin-4 significantly antagonized Aβ-induced spatial learning and memory deficits.
- Exendin-4 rescued long-term potentiation (LTP) impaired by Aβ1-42.
- Exendin-4 counteracted Aβ1-42-induced reductions in hippocampal cAMP and pCREB levels.
Conclusions:
- Exendin-4 demonstrates neuroprotective effects against Aβ-induced cognitive decline.
- The findings support Exendin-4's potential as a therapeutic agent for Alzheimer's disease.
- This study provides a theoretical basis for repurposing T2DM drugs for AD treatment.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
